Telomir Pharmaceuticals, Inc. Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Telomir Pharmaceuticals, Inc. Common Stock generated cash of -$3,859,796, which is less than the previous year. Cash used in financing activities reached the amount of $3,859,608 last year. Net change in cash is therefore -$188.
Cash Flow
| 2022 | -468.66K | 0 | 470.08K |
|---|---|---|---|
| 2023 | -3.85M | 0 | 3.85M |
TELO Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 1.41K | 0 |
Operating activities | ||
Net income | -13.07M | -854.14K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 0 | 0 |
Stock-based compensation expense | 0 | 0 |
| Deferred income tax benefit | 0 | 0 |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 114.55K | 385.48K |
Cash generated by operating activities | -3.85M | -468.66K |
Investing activities | ||
Purchases Of Investments | 0 | 0 |
Investments In Property Plant And Equipment | -4 | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | 0 | 0 |
Financing activities | ||
Common Stock Issued | 1M | 0 |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 3.11M | 462.39K |
Cash used in financing activities | 3.85M | 470.08K |
Net Change In Cash | -188 | 1.41K |
Cash at end of period | 1.23K | 1.41K |
| Data source |